Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA offers clinical trial design on Accelerated Approval

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 09, 2024 11:00am

144 Views

Post# 36031149

RE:RE:RE:FDA offers clinical trial design on Accelerated Approval

What ONCY keeps mentioning is an accelerated pathway to the registration (approval) of pelareorep and from all the evidence and everything mentioned thus far ONCY has its 'fingerprints" all over an "Accelerated Approval".

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"